Abstract: The present invention provides a method for preparing porous organic/inorganic composite powder which includes attaching inorganic oxide nanoparticles in a multi-layer form by repeating steps of attaching polyphenol to porous polymethyl methacrylate (PMMA) microspheres and attaching inorganic oxide nanoparticles to the porous polymethyl methacrylate (PMMA) microspheres to which polyphenol is attached, and a cosmetic composition including the porous organic/inorganic composite powder.

Abstract: Described herein are oral care compositions comprising (i) a peroxide whitening agent comprising a whitening complex of crosslinked polyvinylpyrrolidone complexed with hydrogen peroxide, (ii) sodium acid pyrophosphate (Na2H2P2O7) in an amount of from 0.05 wt % to 5 wt % based on the weight of the composition, and (iii) less than 3 wt % water based on the weight of the composition.

Abstract: Pyruvate may be used to stabilize hyaluronic acid compositions. For example, these compositions may have improved heat and/or storage stability.

Abstract: This invention relates to an odour-absorbing composition comprising a mixture of ?-, ?-, and ?-cyclodextrins, wherein the amount of one of said ?-, ?-, and ?-cyclodextrins is equal to or higher than the total amount of the other two cyclodextrins.

Abstract: Provided are skin care compositions that are useful as SPF and UV absorption boosters in formulations containing inorganic metal oxides. The compositions comprise (a) (a) copolymer particles; (b) voided latex particles; (c) inorganic metal oxide particles; and (d) one or more dermatologically acceptable carriers. Also provided are methods of protecting skin from UVA and UVB damage comprising topically administering such compositions to the skin, and methods of boosting the SPF or UV absorption of a sunscreen composition containing inorganic metal oxide particles comprising including such copolymer particles and voided latex particles in the composition.

Abstract: Mascara compositions that comprise ammonium styrene/acrylate copolymer and acrylates/VA copolymer as a plasticizer, in an aqueous base. In the concentrations specified, herein, the resulting mascara compositions have various useful properties that can be controlled, such as transition temperature, viscosity, dry time and degree of contraction. Compositions of the invention are hydrophilic. Nevertheless, after application, the compositions dry to a contracted hydrophobic state that retains curl. The applied composition resists transfer, smudging, flaking, humidity, oil and sebum, making them very suitable as 24 hour long wear cosmetics. Some preferred embodiments comprise an unusually high concentration of nylon fibers, which enhances volume and lengthening of eyelashes.

Abstract: Provided are compositions and methods that are useful for personal care compositions. The compositions comprise (a) a cationic polymer comprising polymerized units derived from (i) 30 to 80 weight % of cationic monomers, (ii) 10 to 65 weight % of (meth)acrylamide monomers, and (iii) 0 to 30 weight % of polar non-ionic derivatives of acrylic monomers, and (b) at least one cosmetically acceptable surfactant, rheology modifier, or cosmetic active. Also provided are methods of treating hair with such compositions.

Abstract: A hair strengthening, nourishment, and growth composition and method of application that can be used in the form of a shampoo.

Abstract: An injectable carboxymethylcellulose (CMC) and methylcellulose (MC) hydrogel derived from the plant-based polysaccharide, cellulose, is provided which gels in situ and repairs the intervertebral disc in the spinal column or other cartilaginous tissues. One specific application is for replacement of the nucleus pulposus (NP), the central gelatinous region of the intervertebral disc, following injury or degeneration.

Abstract: The present invention relates to improved formulations of Levosimendan for pharmaceutical use, and particularly for intravenous administration as infusion or injection and of infusion concentrates. The present invention therefore relates to pharmaceutical compositions comprising Levosimendan, in which Levosimendan is present in a solubilized form. The formulations have therapeutically and commercial useful concentrations of Levosimendan. The solutions of the invention have enhanced ability at physiological pH (pH 7.4) and are particular useful as infusion or injection solutions or infusion concentrates. The composition according to the present invention can also be spray-dried or lyophilized to obtain a dried powder which is very stable and which powder forms the original solution after reconstitution in water or an aqueous solvent. Levosimendan or (?)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazi-nyl)phenyl]hydrazono]propanedinitrile is useful in the treatment of congestive heart failure.

Abstract: Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.

Abstract: Disclosed herein are compositions and methods for treating lung disorders including lung tumors by pulmonary administration of compositions comprising taxane particles such as docetaxel or paclitaxel particles.

Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).

Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.

Abstract: The invention discloses naltrexone implantable tablets which are devoid of metal salts and corticosteroids, and which provide consistent and controlled amount of naltrexone for 3 months or more; also disclosed is methods of treatment comprising the implants and methods of sterilization of the implants.

Abstract: A composite structural material and pharmaceutical composition comprising same, the use of the composite structural material in preparing a sustained release formulation, and a pharmaceutical composition formulation method; the composite structural material comprises a hydrophobic structural material and a hydrophilic structural material; the proportion of the hydrophobic structural material to the hydrophilic structural material ranges from 1:0.01 to 1:5, preferably 1:0.05 to 1:4, more preferably 1:0.1 to 1:3, and most preferably 1:0.4 to 1:2, such as 1:0.4 to 1:1.3. The pharmaceutical composition comprises the composite structural material and one or more active pharmaceutical ingredients, and preferably the proportion of the composite structural material to the active pharmaceutical ingredients ranges from 1:0.01 to 1:8, more preferably 1:0.02 to 1:5, and most preferably 1:0.03 to 1:1, such as 1:0.3 to 1:0.7.

Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.

Abstract: A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.

Abstract: Particles comprising an opioid receptor antagonist as well as methods of their use and methods of their preparation are provided herein. Such particles may be used for treating and preventing opioid-induced side effects in patients, and may be provided to chronic opioid users as well.

Abstract: The present invention provides compositions useful in reducing or preventing pain in a subject in need thereof. In one embodiment, the compositions comprise a halogenated volatile compound. The present invention further includes a method of reducing or preventing pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of the invention. Dosing regimens contemplated within the invention include one-time administration, continuous administration or periodic administration.

Abstract: The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of hyperhidrosis.

Abstract: The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.

Abstract: The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments.

Abstract: The invention relates to doxepin, pharmaceutically acceptable salts and prodrugs of doxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.

Abstract: The present invention relates to methods of treating overweight or obesity, reducing fat, sugar, and food intake, and reducing body weight or body weight gain in a subject using geranium oil or orlistat mouthwash, or a combination of both.

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

Abstract: This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.

Abstract: Disclosed is a pharmaceutical composition containing silibinin, which is prepared from the following bulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, and 25-200 parts of Pu'er tea extract. The drug has the function of treating non-alcoholic fatty liver.

Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.

Abstract: Methods that include determining levels of melatonin pathway agents (melatonin, L-tryptophan, 5-hydroxytryptophan (5-HTP), serotonin, N-acetylserotonin (NAS), and melatonin receptor 1A (MT1)) in Hypoxic-ischemic brain injury in both newborns (HIE) and adults (stroke), and in ALS, and optionally administering these agents to treat these conditions.

Abstract: Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.

Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof

Abstract: A new derivative of naproxen, 3-((S)-2-(6-methoxynaphth-2-yl) propanoyloxy)-4,5-bis (((S)-2-(6-methoxynaphth-2-yl) propanoyloxy)-methyl)-2-methylpyridinium (S)-2-(6-methoxynaphth-2-yl) propanoate has a high anti-inflammatory, analgesic and antipyretic activity, as well as low acute toxicity and gastrotoxicity, it can be used in the pharmaceutical industry, medicine and veterinary.

Abstract: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.

Abstract: The present invention relates to a pharmaceutical composition comprising an amorphous adsorbate of lenalidomide, or a pharmaceutically acceptable salt thereof, on a porous carrier and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of multiple myeloma and myelodysplastic syndromes.

Abstract: The present invention relates to the use of an inseparable combination of morphine and at least one opiate antagonist with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for treatment of opiate dependency in humans and to the use of an inseparable combination of an opiate and at least one opiate antagonists with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for prevention of non-oral opiate abuse in opiate addicts.

Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.

Abstract: The invention refers to the use of Reverse Transcriptase (RT) inhibitor compounds for the preparation of pharmaceutical compositions to counteract the loss of cellular differentiation in tumour and non tumour pathologies, said compound being able to bind the hydrophobic pocket on the RT subunit p66. Particularly preferred for such uses are the following compounds: nevirapine, efavirenz, delavirdine, corresponding salts and/or pharmaceutically acceptable derivatives thereof.

Abstract: Compositions, packaged pharmaceuticals, and methods of treatment by the sensitization of resistant tumors are provided. The compositions comprise a combination of a hedgehog pathway modulator, such as itraconazole, and a chemotherapeutic agent. Tumor cells in mammalian subjects treated with the hedgehog pathway modulator are sensitized to the effects of the chemotherapeutic agent, thus increasing the therapeutic index of the agent and reducing toxicity to the subject.

Abstract: The invention relates to quinazoline derivatives substituted by aniline which are represented by the below formula (I), pharmaceutical acceptable salts and stereoisomer thereof, wherein these groups of R1, R2, R3, R4, R5, R6, L and n have the meanings given in the specification. The invention also relates to preparation methods, pharmaceutical compositions, pharmaceutical preparation and the use for preparation of medicine of treating excessive hyperplasia and chronic obstructive pulmonary disease and uses for treating excessive hyperplasia and chronic obstructive pulmonary disease thereof.

Abstract: Compositions containing and methods of administering TH-4000 are useful in treatment of cancer alone or in combination with other anti-cancer agents.

Abstract: A method of treating demyelinating diseases involves administering a PAK1 inhibitor that is PF-3758309 to a subject in need of such treatment.

Abstract: A method for treating cancer including administering to a patient in need thereof an effective amount of a compound having the formula: wherein R1, R2, Ya, Xa, and J? are as defined herein, and may be where R1 and R2 are independently selected from methyl, ethyl, n-propyl, or i-propyl; Xa is N or CH; Ya is hydrogen or independently selected from halogen, cyano, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, heteroaryl of 6 members and aryl; n is 1 or 2; wherein J? is fluoride, chloride, bromide, iodide, acetate, sulfate or sulfonate such as tosylate, mesylate, besylate.

Abstract: Gold(I)-carbene complexes having a selenium donor ligand with anti-cancer activity and a method of treating cancer. Methods of treating cancer comprising administering the complexes are also provided.

Abstract: Disclosed herein is a pharmaceutical composition comprising pharmaceutical formulation of complexed Celecoxib and crystalline Celecoxib to provide fast and long lasting continuous pain management with once a daily dosing. The pharmaceutical composition has improved physicochemical properties that provide faster onset of action for acute pain relief and lower GI related side effects for acute pain relief and lower GI related side effects.

Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.

Abstract: A method for olfactory improvement with saccharide. The saccharide is a chitin-based material, proteoglycan, glycosaminoglycan, amino monosaccharide, N-acylated amino monosaccharide or a combination thereof.

Abstract: Described are kits, food compositions and methods for cleaning the bowel, e.g., in preparation for a medical procedure, e.g., a diagnostic or treatment procedure, such as an endoscopic or surgical procedure, or radiologic imaging such as CT colography.

Abstract: The method for treating cardiovascular disease relates to stopping growth of an atherosclerotic plaque or lesion. A therapeutically effective amount of a pharmaceutically acceptable gallium compound is administered to an inflammation site in an artery with a lesion with microcalcifications. Gallium ions bind to the lesion. The proper amount of gallium compound delivered to the lesion disrupts a calcification process at the inflammation site. The gallium ions bind to calcium hydroxyapatites in microcalcifications so that the microcalcifications can no longer differentiate into early phase osteoblasts. The gallium integrated into the calcium structures at the inflammation site has a lasting effect to reduce atherosclerotic plaques.

Abstract: Provided are methods for administering multiple doses of cells, such as T cells, to subjects for cell therapy. Also provided are compositions and articles of manufacture for use in the methods. The cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods generally involve administering a first and at least one consecutive dose of the cells. Timing of the doses relative to one another, and/or size of the doses, in some embodiments provide various advantages such as lower or reduced toxicity and improved efficacy, for example, due to increased exposure of the subject to the administered cells. In some embodiments, the first dose is a relatively low dose, such as one that reduces tumor or disease burden, thereby improving the efficacy of consecutive or subsequent doses, and the consecutive dose is a consolidating dose.